Our Company

Kosuke Iwasaki, FIAJ, MAAA

Director, Japan Healthcare Practice and Data Analytics
Tokyo, JP

Tel: +81 3 52117031

E-Mail | Download bio | VCard

Professional Designations

  • Fellow, Institute of Actuaries of Japan
  • Member, American Academy of Actuaries

Education

  • BS, Mathematics, The University of Tokyo
  • MBA, Columbia University

Current Responsibility

Kosuke Iwasaki joined Milliman's Tokyo office in 1999 and moved to New York in 2000. As a consulting actuary in healthcare and life insurance, he has contributed to or managed projects with life/health insurance companies, pharmaceutical companies, medical device companies, disease management companies, managed care organizations, and research institutes.

After 13 years in New York, he returned to Milliman's Tokyo office in July of 2013 to establish the firm's healthcare and data analytics practice in Japan.

Experience

  • Health technology assessment (HTA) including cost-effectiveness, cost-utilization, and cost-benefit analysis for pharmaceutical companies and medical device companies
  • Economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
  • Economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
  • Economic value of bariatric surgery
  • Economic value of disease management programs and screening
  • Analysis on adverse drug events for hospitals
  • Value-based design of health insurance, including the cost-sharing structure of diabetes drugs and chemotherapy for cancer patients
  • Development of a predictive model for a disease management company in Japan
  • Development of a predictive model for long-term care cost
  • Development of budget impact models (BIMs) for drugs for diabetes and hepatitis C patients
  • Development of benchmarks on outcomes for hospitals
  • Stochastic modeling, including:
    - Generalized linear model (GLM)
    - Survival model
    - Hierarchal Bayesian model
    - Bayesian network model
  • Development of healthcare reform models for accountable care organizations (ACOs)
  • Development of health insurance products, disability income products, long-term care products, and critical illness products for life and health insurance companies
  • Pricing and profit testing of insurance policies
  • Due diligence in M&A of life/health insurance companies

He is a member of the Institute of Actuaries of Japan's Health Insurance Committee.

  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman